Patent ID: 11865088
Assignee: CLEXIO BIOSCIENCES LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 16:
17. A method of treating major depressive disorder (MDD) in a human patient in need thereof consisting essentially of
orally administering to said patient an oral dosage form of between 20 mg and 40 mg of esketamine over a treatment regimen of at least 28 days;
and optionally administering to said patient a second medication that is an antidepressant, an antimanic agent, or an anxiolytic drug that does not alter the metabolism of the esketamine in the patient, wherein the ratio of S-norketamine Cmax to esketamine Cmax after the coadministration of the esketamine and the second medication is at least 6;
wherein the administration results in a reduction in the human patient's symptoms of MDD, when measured at at least day 28 as compared to placebo.